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The prevalence of asthma in the most advanced ages is similar to that of younger ages. However, the concept that
older individuals may suffer from allergic asthma has been largely denied in the past, and a common belief
attributes to asthma the definition of “rare” disease. Indeed, asthma in the elderly is often underdiagnosed or
diagnosed as COPD, thus leading to undertreatment of improper treatment. This is also due to the heterogeneity of
clinical and functional presentations of geriatric asthma, including the partial loss of reversibility and the lower
occurrence of the allergic component in this age range. The older asthmatic patients are also characterized the
coexistence of comorbid conditions that, in conjunction with age-associated structural and functional changes of
the lung, may contribute to complicate the management of asthma. The current review addresses the main issues
related to the management of allergic asthma in the geriatric age. In particular, the paper aims at revising current
pharmacological and non pharmacological treatments for allergic asthmatics of advanced ages, primarily focusing
on their safety and efficacy, although most behaviors are an arbitrary extrapolation of what has been tested in
young ages. In fact, age has always represented an exclusion criterion for eligibility to clinical trials. Experimental
studies and real life observations specifically testing the efficacy and safety of therapeutic approaches in allergic
asthma in the elderly are urgently needed.
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The world population is ageing, and life expectancy
(meaning the number of years an individual can expect
to live) is steadily increasing. Because of increased lon-
gevity, the proportion of individuals aged 65 years and
older (referred to as the elderly) is growing worldwide.
Given these demographic changes, the impact of asthma
is expected to rise in the next years. The management of
asthma in the elderly follows international guidelines
that apply to all ages, although most recommendations
are an arbitrary extrapolation of what has been tested in* Correspondence: nicola.scichilone@unipa.it
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unless otherwise stated.younger subjects. In fact, age has always represented an
exclusion criterion for eligibility to clinical trials. Many
specific factors affect treatment of the elderly. They
often undertake a number of medications as they fre-
quently suffer from different diseases and comorbidities.
Polypharmacy increases the risk of low adherence and of
interactions between different drugs. Furthermore eld-
erly patients may present cognitive dysfunction that re-
sults in a decreased memory, which in turn affects the
compliance to the treatments. The changes in body com-
position and metabolism that characterize aging process
should also be carefully taken into account. The pharmaco-
logical effect of systemic drugs may be affected by the re-
duced activity of kidney and liver and by the decrease in
muscle mass, fat and body water. In elderly individuals with
respiratory allergies, the ‘course’ of the disease is consideredtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cific immunotherapy is considered very limited. Physicians
often face the requests of patients who ask for complemen-
tary/alternative medicines (CAMs). Thus, it is urgent to be-
come aware of the efficacy and contraindication of CAMs
in order to provide patients with scientifically-supported
information, especially in older populations. Strategies to
increase physical and sports activity participation among
older people should include the awareness of the benefits
and minimize the perceived risks of physical activity.
Despite advances in the management of asthma independ-
ently of age, there is an urgent need for targeted, disease-
modifying asthma treatments. It is necessary to clearly
identify clinical phenotypes to achieve optimal treatment of
elderly patients with asthma. It is clear that the delivery of
biologics or advanced immunotherapy requires a special
attention in the elderly, where comorbidities are often
present.
The current article undergoes the main aspects of
pharmacological and non pharmacological approaches to
asthmatic subjects of advanced ages, with special focus
on safety issues, and highlights the practical consider-
ations to be taken into account when managing elderly
asthmatics in clinical settings.
Inhaled treatment
Corticosteroids
Inhaled corticosteroids (ICS) are widely used in the
treatment of patients with asthma, in that, they repre-
sent the cornerstone of the pharmacological manage-
ment of the disease. However, high-dose regimens and
long-term use of ICS may be associated with increased
risk of side-effects, which are mostly important in the
elderly populations. The GINA guidelines [1] clearly
state that asthma treatment in the elderly is complicated
by several factors, such as the reduced coordination be-
tween activation of the device and inhalation of the
drug, which can affect the lung deposition on one hand
(thus reducing the efficacy), and can increase the oral
deposition on the other hand (thus causing local and
systemic adverse events). In addition, the increased
number of comorbidities and their associated symptoms
and treatment may interact to various extent with the
pharmacological treatment for asthma, potentially lead-
ing to serious side effects.
The pharmacokinetic and pharmacodynamics fea-
tures of the ICSs are influenced by several factors, such
as the particle size and the formulation of the aerosol.
These factors can affect the systemic bioavalaibility,
which is responsible for the potential suppression of
the hypothalamic-pituitary-adrenal axis. The bioavail-
ability is also influenced by the protein binding and the
process of bioactivation by first pass metabolism of the
liver. All these passages can be altered in the mostadvanced ages, and should be taken into account, by
using the minimum efficacy dose of ICS.
With no doubt, the most serious potential side effect
is the increased incidence of pneumonia, which has been
observed in patients with COPD both in controlled clin-
ical trials and case–control analyses [2]. There is evi-
dence that the occurrence of pneumonia is associated
with the use of ICS also in asthma [3]. Because of the
long-term use of ICSs, safety concerns have been raised
with regard to osteoporosis and risk of fractures [4], al-
though the occurrence is much lower in comparison
with the use of systemic corticosteroids. The clinical im-
plications for elderly asthmatics may not be trivial, since
these subjects will likely continue to be exposed to high
doses of ICS over many years.
Patients and physicians are often concerned about the
use of ICSs and the occurrence, or worsening, of dia-
betes. Suissa and collaborators [5] found that ICS use
was associated with a 34% increase in the risk of incident
diabetes, defined as initiation of anti-diabetic medications,
in a dose–response fashion. Moreover, in patients already
treated for diabetes with oral hypoglycemic agents, the risk
of progression to insulin also increased significantly with
the use of ICS. With regard to the occurrence of glaucoma
and cataract, the available literature has not confirmed the
link with the chronic use of ICS [6,7], although a careful
check for ocular abnormalities and the monitoring of ocu-
lar pressure is always recommended. Local side effects,
such as oral, pharyngeal and even esophageal candidiasis
are common adverse effects of ICS. However, little is
known about the prevalence in the elderly. It is logical to
assume that factors such as the patient’s inhalation tech-
nique, patterns of inhalation and peak inspiratory flow, all
of which are variably impaired in elderly patients, can
increase the occurrence of these side effects in the most
advanced ages [8,9].
Beta-2 adrenergic agonists
Beta-2 agonists, both short- and long-acting (SABA and
LABA), are widely used in elderly asthmatic patients and
their efficacy is well established [8,10]. Aside the valid
and prolonged bronchodilator effect, long-acting mole-
cules may also exert a beneficial steroid sparing action if
added to moderate dose inhaled corticosteroids instead
of increasing the use of the latter. The chronic use of
beta-2 agonists can however lead to the onset of toler-
ance. This has been mainly reported in specific pheno-
types of asthma like exercise-induce bronchoconstriction
(which shares a prevalent neutrophilic inflammatory pat-
tern with elderly asthma) and in peculiar subpopulations
of subjects, despite data in aged patients are not avail-
able in literature. Furthermore, responsiveness to this
class of drugs may decline with age, due to a beta-
adrenergic dysfunction [10]. In addition, clinicians should
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advising any patient using them more than twice weekly
to return for reassessment of asthma control.
Besides these general indications, there are certain
therapeutic concerns related to the beta-2 adrenergic ad-
ministration, unique to older patients, which deserve to
be addressed. Among these, the most important seems
to be the greater probability of adverse effects, in the set-
ting of multiple comorbidities [11]. Hypokalemia, QT
prolongation, tachycardia and tremor are the side effects
more commonly reported in association with these
agents. They are mediated by the systemic drug absorp-
tion and are dose dependant. In particular, the incidence
of dysrhythmias after the administration of nebulized
beta-2-agonists is well recognized and it has been re-
ported to be as high as 65% [12]. However, clinical trials
have not specifically addressed the use of SABA and
LABA in elderly asthmatic patients. This is unfortunate,
since the incidence of ischemic heart disease and the co-
existence of other cardiovascular disorders increase with
age, and many patients with chronic lung disease are
smokers. Furthermore, beta-2 agonists cause a net influx
of intravascular potassium into cells with subsequent
hypokalemia. Older patients taking diuretics or insulin,
as well as those with poor nutritional intake have a
greater incidence of hypokalemia and are thus at greater
risk of developing this common electrolyte disturbance.
Anticholinergics
The use of anticholinergic drugs in elderly should take
into consideration the detrimental effect of aging on the
parasympathetic activity and the possible occurrence of
adverse events. Ipratropium bromide is a short-acting
anticholinergic bronchodilator that is routinely used for
COPD, and is less commonly used as first-line therapy
to treat asthma. However, ipratropium is often pre-
scribed in combination with albuterol for the treatment
of acute exacerbations of asthma in emergency rooms.
Results of previous research studies showed the benefit
of using the combination therapy in adults with acute
asthma (mean age 34.3 ± 10.5 years), leading to a de-
creased rate of hospital admission compared with albu-
terol alone [13]. Tiotropium has been considered as
add-on therapy to ICS and LABA, and the results of ran-
domized controlled trials suggest a significant effect on
lung function. However, all trials enrolled adults with an
overall mean age of 49 ± 11 yrs, preventing, at present,
definitive conclusion about the efficacy of tiotropium in
elderly asthmatics [14-16].
Long acting anticholinergic are well tolerated in the eld-
erly. Dry mouth, and unpleasant taste can occur and these
adverse events can contribute, in older people, to reduced
ability to speak, mucosal damage, denture misfit, poor ap-
petite, malnutrition risk and respiratory infection due to thereduction of antimicrobial activity of saliva. In males, urin-
ary outflow can be observed and a reduction of gastrointes-
tinal motility has been documented in adults. Moreover,
anticholinergics increase intraocular pressure and can cause
dilatation of pupil and blurred vision. Cardiovascular ef-
fects have been deeply explored in COPD patients, and
the available results regarding their safety may be consid-
ered encouraging. Due to the reduced metabolism and
drug elimination in older patients, anticholinergic drugs
may induce, in continuous users, mild cognitive impair-
ment. Finally, in 3 patients out 1000 a paradoxical bronch-
ocostriction may occur [17]. On the basis, the use of long
acting anticholinergic drugs should be limited to elderly
people that remain uncontrolled despite ICS and LABA
use, LABA intolerance and ineffectiveness of other thera-
peutic approaches.
Systemic treatment
Systemic glucocorticoids
Systemic glycocorticoids (mainly administered by oral
route) are listed as second line option in GINA guide-
lines step 5 and at low dose (i.e. < 7.5 mg/die equivalent
of prednisone). Their use is limited to adults with poor
control and reserved to elderly patients who may have
more benefit than side effects, which increase with the
dose administered. They are to be administered when
flares-up of symptoms develop in the course of well-
controlled treatment and when acute emergency occurs,
including hospital care. Use of oral steroids in asthma
was more liberally prescribed in the past, when the con-
cepts of steroid-resistance and dependence were devel-
oped. Nowadays, systemic steroids are the final approch
when all other strategies have failed or are not applic-
able. About 40% of asthmatic patients above 75 yrs of
age do not control their asthma, and this is only partly
related to cortisonophobia of both patients and doctors.
Obesity is another factor predisposing to diminished
steroid response, even after adjusting for body weight.
When serious life threatening acute episodes occur, or on
emergency hospital admission, prednisolone at 1/mg/kg
(with maximum of 50 mg) is recommended [18]. From a
clinical perspective, it is interesting to point out that oral
route (when not contraindicated) is as efficacious as the
intramuscular or intravenous routes. Therapy should not
exceed seven consecutive days, but no problems arise
from abrupt discontinuation for treatments below 14 days.
Beyond this time frame, a gradual titration of oral steroids
is advisable.
Side effects due to systemic glycocorticoid treatment in-
clude glucose intolerance (usually reversible or controlled
by treatment), gastrointestinal bleeding (in patients with
known disease or gastrectomized for previous ulcers) and
blood pressure control (not a main problem since step-up
antihypertensive therapy controls the increase). Depression
Scichilone et al. Clinical and Molecular Allergy  (2015) 13:7 Page 4 of 14and changes of mood are frequent, especially in the
elderly populations, and other side effects such as cath-
aract, glaucoma, osteoporosis and adrenal insufficiency
may occur in the long-term treatment. The danger of
immunosuppression is not common and it is even less
frequent than with inhaled corticosteroids (i.e. candidiasis,
tuberculosis). When elderly patients are discharged from
hospital, adherence to treatment abruptly ceases and a
flare-up of symptoms after discontinuation of systemic
steroids is considered a bad prognostic sign and indication
of greater severity of asthma [19].
Leukotrienes antagonists
There are two different licensed leukotriene (LT) Antag-
onists (LTRA) for asthma treatment: a) a 5- lipoxygenase
enzyme inhibitor named zileuton, and three LT-1 antag-
onists named montelukast, pranlukast, zafirlukast. In the
COMPACT [20] study montelukast showed its ability to
spare on ICS dosage doubling ICS to obtain asthma con-
trol; while in the IMPACT [21] study montelukast
showed its ability to be an alternative to salmeterol in
patients treated with fluticasone propionate. When con-
sidering this option in the elderly, a recent observational
study on asthmatics ≥65 yrs reported that about in a
quarter of them montelukast was used as add-on therapy
to a LABA/ICS combination [22]. Theoretically, monte-
lukast could be of interest in the treatment of asthma in
the elderly, as it could contribute to obtain symptom
control by enhancing patients’adherence, frequently re-
duced in the elderly [23], increasing the efficiency of
asthma therapy, by counterbalancing well-known errors
in managing inhaler devices, also frequent in the elderly
[24], and avoiding ICS and LABA side effects, reported
with higher frequency in the elderly [25], and considered
a component of the future risk of asthma. It is of interest
the ability of LTRA to be an alternative to β2 agonists
when hypertension and/or hearth failure and/or chronic
ischemic heart disease are present, becoming the first-line
drugs for elderly asthmatics with a history of cardiovascu-
lar events. Moreover, avoiding a low dose ICS or sparing
on its doubling dosage may be useful when comorbidities
are present (osteoporosis, diabetes, glaucoma, cataract). In
one double blind, randomized, placebo-controlled study
on subjects aged >60 yrs with severe asthma, control was
improved by adding montelukast to LABA/ICS com-
bination. Subjects experienced reduced exacerbations,
asthma symptoms and salbutamol use [26]. The au-
thors hypothesized that these positive effects were due
to higher adherence to the once daily oral treatment
with added montelukast. However, a retrospective ana-
lysys on five clinical trials [27] comparing zariflukast
and fluticasone propionate did not show any significant
benefit on a population aged >50 yrs. A recent revision
of Scichilone et al. [28] on the safety and efficacy ofmontelukast in the elderly population is reassuring
about safety, but is unable to conclude for a superior
efficacy of LTRAs in this setting. However, the authors
concluded that in the elderly population LTRAs, and
particularly montelukast, may represent a more effect-
ive strategy in improving asthma given unintentional
nonadehrence with inhalation therapy.
Theophyllines
Theophylline, a methylxanthine, has been used as a bron-
chodilator in the treatment of asthma for more than
80 years, and remains a widely prescribed drug, because it
is cheap and readily available [29]. Unfortunately, relatively
high doses of theophylline are required to obtain a bron-
chodilator effect (10–20 mcg/ml), and this is associated
with high incidence of side effects, mostly due to adenosine
antagonism [30]. Theophylline treatment is also limited by
its narrow therapeutic range, variable inter-patient pharma-
cokinetics, and multiple drug interactions. However, in re-
cent years, the interest for theophylline is reborn through
the demonstration of its anti-inflammatory activity [29,31].
Actually, even at low therapeutic concentrations (5 mcg/
ml) it is able to activate the histone deacetylases, especially
when their activity is reduced by oxidative stress, as in
smokers [32].
In general, the use of theophylline is limited by its ad-
verse effects, which range from commonly occurring
gastrointestinal symptoms to palpitations, arrhythmias,
rarely myocardial infarction and seizures. Theophylline
is metabolized primarily by the liver, and commonly
interacts with other medications. The available data indi-
cate that the clearance of theophylline is reduced by 22-
35% in elderly people, and that it is furtherly decreased by
concomitant diseases, particularly liver (50% decrease)
and heart (50% decrease) disease. Theophylline clear-
ance is also influenced by diet: low carbohydrate/high
protein diets, parenteral nutrition, and daily consump-
tion of charcoal-broiled beef increase the clearance and
decrease half-life. Curiously, theophylline clearance is
increased by 80% in elderly tobacco smokers. However,
appropriate studies have not demonstrated geriatric-
specific problems that would limit the usefulness of
theophylline in the elderly. In conclusion, the main
roles of theophylline in asthma of the elderly are in se-
vere disease as an adjunct to ICS and LABA, particu-
larly in conditions of corticosteroids resistance and in
smokers [33]. Caution and close monitoring of plasma
theophylline concentration are required in the elderly.
The phosphodiesterase (PDE) 4 inhibitor roflumilast
is available for COPD treatment, and its use in asthma
can be an interesting add-on therapeutic option in se-
vere asthma with frequent exacerbation and neutro-
philic inflammation. Its therapeutic use of is limited by
side-effects, which are dose-dependent and the range of
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efficacy was found between older and young patients
and no cardiovascular risks emerged in studies [34].
The main limitations are associated with class-specific
side effects such as emesis, reported as a dose-limiting
side effect, nausea and diarrhea. Weight loss is a major
concern, reported in daily clinical settings.
Monoclonal antibodies
To date, omalizumab, a monoclonal anti-IgE humanized
antibody, is the only specific target therapy available,
and recognised as an add-on therapy in severe persistent
asthmatics with inadequately controlled symptoms, re-
gardless of age. Despite the high safety profile of omali-
zumab, an association between the use of omalizumab
and the occurrence of hyperglycemia has been recently
documented, and related to the sucrose contained in the
vials [35]. Taking into account the incidence of diabetes
in elderly patients, clinicians must control the blood
levels of glucose in asthmatic patients during omalizu-
mab treatment.
Infliximab, a chimeric anti-TNF-α monoclonal antibody
(mAb) and etanercept, a soluble TNF-α receptor linked to
human Fc of IgG1, showed significant improvements in
lung function and in the exacerbation rate, particularly in
patients with severe steroid-resistant asthma. However,
conflicting efficacy results obtained with other TNF-α
blockers have cooled the use of these biologicals in asth-
matic patients [36]. The crucial role of IL-5 in eosinophil
activation, maturation and survival makes it an interesting
drug target. In fact, the inhibition of eosinophil accumula-
tion in the airway wall of asthmatic patients by using mepo-
lizumab and reslizumab, two humanized anti-IL-5 mAbs,
and benralizumab, an anti-IL-5 receptor represent novel
therapeutic strategies. IL-4 is an established clinical target
and a key factor in airway inflammation and IgE synthesis
by B cells; however, despite initially promising findings with
biologics able to block its functions (pitrakinra, pascolizu-
mab, dupilumab), subsequent trials are needed before its
clinical application [37]. In conclusion, other than the anti-
IgE mAb omalizumab, novel therapies are currently being
explored to overcome the difficulties of severe asthma, even
though no specific treatment are dedicated to older asth-
matic patients.
Specific immunotherapy
Subcutaneous immunotherapy
Subcutaneous immunotherapy (SCIT) is the historical
route of administration and consists of allergen extract in-
jections which can only be performed with a medical obser-
vation. The guidelines on the treatment of allergic diseases
rarely focus on the elderly population and often ignore this
population completely. Several placebo-controlled studies
that demonstrated efficacy have included subjects up to60 years of age. Unfortunately, studies that support the
safety and effectiveness of SCIT in the elderly are not
blinded. The European Academy of Allergy and Clinical
Immunology advises specific immunotherapy as a re-
lative contraindication for elderly patients [38]. The
Canadian Society of Allergy and Clinical Immunology,
in its guidelines for the use of immunotherapy, does
not contraindicate this treatment for aged patients [39].
However, the presence of co-morbid cardiac or pulmonary
conditions might increase the risk of a poor outcome fol-
lowing a systemic reaction. Other factors/co-morbidities to
consider before starting immunotherapy in the elderly are:
severe or unstable asthma, beta-adrenergic blocker and
angiotensin converting enzyme inhibitors (ACEI) therapy,
autoimmune diseases, and neoplastic diseases. There are
potential elements of risk that can be influenced by beta-
adrenergic blockers in the setting of vaccine administration.
Reactions might be more frequent, more severe, and refrac-
tory to treatment [40]. Concomitant treatment with beta-
adrenergic blockers does not appear to increase the risk for
sistemic reaction to SCIT, but may result in more pro-
tracted and difficult to treat anaphylaxis. There is an
ongoing debate on whether ACEI should be substituted
prior to initiation of immunotherapy for safety reasons [41].
The medical literature reports no double blind placebo con-
trolled (DBPC) studies specifically evaluating the efficacy of
SCIT in elderly asthmatic patients. However, the prevalence
of IgE-dependent allergic rhinitis and other atopic diseases
in elderly patients is reportedly increasing. Based on the
lack of the studies conducted to date, there is a clear need
to design DBPC studies on a large scale with a significant
number of patients enrolled to evaluate the efficacy and
safety of the immunotherapy in the elderly; then it will be
essential to confirm the results obtained in these large stud-
ies in the real-life setting [42].
In conclusion, we are in agreement with the state-
ments reported in the “Third Update Practice Parameter
on Allergen Immunotherapy” which recommend that the
risk/benefit assessment for SCIT should be carefully eval-
uated in the elderly population because they might have
co-morbid medical conditions that could increase the
risks [43]. However, there is no absolute upper age limit
for initiation of SCIT. Contraindications to immunother-
apy in elderly patients are medical condition that reduce
the patient’s ability to survive a systemic allergic reaction
(i.e., patients with markedly compromised lung function),
poorly controlled asthma, unstable angina, recent myocar-
dial infarction, significant arrhythmia, and uncontrolled
systemic hypertension.
Sublingual immunotherapy
The awareness of the efficacy and safety of allergic spe-
cific sublingual immunotherapy (SLIT) in geriatric pa-
tients is sometimes controversial. In part it is also due to
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impact on health care costs in this age of life. In
addition, it is generally known that the immune system
in the elderly is down-regulated in comparison with
young people and that allergies do not occur, so as not
to require any more therapy. However, the reports of in-
creased levels of total and specific IgE and consequent
increase in immunological disorders are raising in litera-
ture in the last few years [44]. From the economic point
of view, the impact of this treatment on the direct and
indirect costs should also be outlined. Two prospective
assessments of treatment in sublingual tablets for grasses,
conducted in the Northern and Southern Europe, have
shown that SLIT is a treatment with a favorable cost/
effectiveness ratio [45,46].
Recently, it has been proved that the dendritic cells
(DCs) in the elderly have an activated phenotype and an
increased secretion of pro-inflammatory cytokines, which
are responsible for the infiltration of eosinophils, the air-
way remodeling and the increase of asthma and chronic
respiratory diseases [47]. In the SLIT the oral DCs are the
first structures involved in the mechanism, with the aim
to modulate the allergen-specific antibody responses. With
particular reference to the geriatric age, compared to sub-
cutaneous therapies it has the advantage of a home man-
agement that greatly simplifies the life of old people, who
generally have difficulties in moving. In a retrospective
study, Marogna et al. [48] evaluated the effect of SLIT in
older patients sensitized to house-dust mite in the preven-
tion of rhinitis and asthma progression, but also in redu-
cing the symptoms and consumption of drugs. This was
recently confirmed in a double-blind placebo-controlled
study in patients over 60 years of age [49].
The safety of SLIT is confirmed by the fact that after
more than 500 million doses administered to humans and
20 years of use there are no reports of fatalities; only few
cases of anaphylaxis have been reported [50]. According
to the Bozek et al. [49], only three patients among the eld-
erly had local common side effects such as oral itching
and facial flushing. No severe adverse reactions were ob-
served in the active group during the study, thus confirm-
ing that SLIT is well tolerated in elderly patients.
However, the compliance to SLIT may represent a major
problem in real life, especially in the elderly populations.
SLIT has been demonstrated to reduce significantly
both symptoms and medications, thus improving quality
of life (QoL) [51]; this could be of great importance with
regard to the elderly population. In fact, recent studies
point out that the quality of life is significantly reduced
in old people with allergic rhinitis in comparison with
young people, and it can also alter the cognitive function
or the mood [52].
In conclusions, SLIT is an effective and safe thera-
peutic option, and the only approach that can changethe course of allergic respiratorydiseases; however, its
use in the elderly is still not widespread. A prerequisite
before starting on a SLIT, especially in the geriatric pa-
tient, is to involve the allergic patient through correct in-
formation about the various aspects of his disease: from
diagnosis, pharmacological treatment options, costs, side
effects, management methods, thus to verify if the pa-
tient is able to deal with the SLIT.
Probiotics
The United Nations Food and Agricultural Organization
and the World Health Organization define probiotics as
“live microorganisms, which, when administered in ad-
equate amounts, confer a health benefit to the host” [53].
Prebiotics are defined as non-digestible oligosaccharides,
such as fructo-oligosaccharides and trans-beta-galacto-
oligosaccharides, that selectively stimulate the growth
of bifidobacteria and lactobacilli, thus producing a pre-
biotic effect. Synbiotics is a term referring to the use of
both prebiotics and probiotics simultaneously. In tax-
onomy terms, the most commonly used probiotic bacteria
are species of the genera Lactobacillus and Bifidobacter-
ium. There are several mechanisms by which probiotics
are proposed to exhibit beneficial effects on the host: most
probably probiotics can modulate the toll-like receptors to
promote TH1-cell differentiation, inhibition of antigen-
induced T-cell activation and suppression of TNF [54]: the
resulting stimulation of Th1 cytokines can suppress Th2
responses. A variety of human studies on the effects of
probiotics administration on the management of various
allergic diseases have been performed to examine the effi-
cacy of probiotics in many allergic conditions, such as ec-
zema and food allergy but there are limited studies on the
effect of probiotic treatment for asthma that do not allow
the reader to extract concrete conclusions that would be
useful for everyday practice [55]. In addition, there is no
study specifically addressing the use of probiotics in eld-
erly asthmatics, and therefore no indication can be posed
for this phenotype.
Vaccinations
In older people, alterations of both innate and acquired
immunity have been shown (Table 1), resulting in an
increased susceptibility to infectious diseases. Viruses,
including influenza, cause acute exacerbations of asthma
in as many as half of adult subjects presenting to emer-
gency rooms. Vaccines play a major role, potentially pre-
venting or worsening of asthma symptoms. Therefore,
vaccines, such as against influenza and pneumococcus,
should be administered to these patients. Asthma was
the most common underlying condition among old indi-
viduals hospitalized with pandemic influenza A (H1N1)
infection [56]. All asthmatics should receive an influenza
vaccination annually [57]. This is in accordance with the
Table 1 Immunological changes occurring in older
individuals compared to younger ages
• Reduced number and function of hematopoietic stem cells
• Thymic involution
• Reduced circulating naive T cells
• Increased frequencies of well-differentiated memory CD28− T cells
with limited proliferative potential
• Increased levels of many proinflammatory cytokines, including
interleukin (IL)-6 and TNFα
• Decreased CD4/CD8 ratios
• Senescence of epithelial cells of the lung
• Augmented neutrophils in the airway
• Reduced function of eosinophils
• Decline in the amount of macrophages and cytotoxic natural killer cells
• Reduced capacity to stimulate antigen specific T cells of dendritic cells,
• Reduced oxidative burst, phagocytic capacity and bactericidal activity
of neutophils
• Reduced oxidative burst and phagocytic capacity of macrophages
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Services, which recommends multicomponent inter-
ventions aimed at increasing influenza vaccination
coverage [58]. In addition, asthma education for health-
care professionals should include recommendations for
influenza vaccination for all patients with current
asthma. Although it was hypothesized that influenza
vaccination may cause wheezing and adverse effect on
pulmonary function, there is no significant increase in
asthma exacerbations immediately after vaccination in
adults or children over 3 years of age.
Respiratory bacterial infections are among the most
important causes of morbidity and mortality from com-
municable diseases worldwide. Streptococcus pneumo-
niae frequently colonizes the upper respiratory tract.
Local host immunity is essential to control colonizing
pathogens by preventing overgrowth, spread, and invasion.
Asthma is commonly considered an independent risk fac-
tor for invasive pneumococcal disease. The pneumococcal
conjugate vaccine, PCV13, is currently recommended for
all adults 65 years or older, in particular in older asth-
matics. The 23-valent pneumococcal polysaccharide vac-
cine PPSV23 is also recommended for use in adults of
65 years of age who smoke cigarettes or who have asthma.
Physicians and other health care professionals should
therefore encourage vaccinations in elderly asthmatic
patients.
Alternative medicines
The use of Complementary/Alternative Medicines (CAMs)
is an impressive emergent phenomenon in Western Coun-
tries. This widespread use is common at any age, including
older people [59]. Bronchial asthma is an important fieldfor CAM, where homeopathy, acupuncture, herbal medi-
cines and yoga are the most utilized techniques [60]. The
reasons for using CAMs usually reported by patients are: a
distrust in conventional medicine, the belief that CAMs are
more natural and safe, and the need for a more strict rela-
tionship with the physician [60]. Due to the large diffusion
of CAM, the high prevalence of allergic diseases, and the
not negligible costs, it is definitely needed that proofs of ef-
ficacy are incontrovertible [61]. Only randomized con-
trolled trials can be suitable for the evaluation of CAM
efficacy and safety. However, the vast majority of the clin-
ical trials published up today with CAMs have a low quali-
tative level [62], thus making the results often difficult to
interpret. On the other hand, it is claimed that “holistic”
approaches cannot be standardized and submitted to
rigorous study designs, because the standardization itself
introduces a confounding factor [63]. Finally, it has to be
considered that some of the CAM techniques are self-
applied (Yoga, relaxation techniques, biofeedback) and
therefore cannot be blinded.
Acupuncture
Acupuncture is a cornerstone of the Traditional Chinese
Medicine, and is widely used for chronic illness, includ-
ing asthma. The most recent reviews [64] included 11
studies with 324 participants: trial reporting was poor,
and quality was judged insufficient. Indeed, looking only
at those studies performed with a rigorous methodology
(i.e. randomized, controlled and blinded), the effects of
acupuncture are not different from the placebo treat-
ments. Thus, the conclusion derived from meta-analysis
studied and clinical trials is that acupuncture is not effect-
ive to treat asthma, although a powerful placebo effect of
acupuncture as rescue medication was demonstrated [65].
Homeopathy
Homeopathy is based on the belief that symptoms of a
disease can be cured by the same substance that provokes
them, if given at ultra-dilution. Homeopathic remedies are
therefore chosen according to symptoms, not to disease,
and prepared with a special manual technique called
“potentiation”. Homeopathy has been extensively stud-
ied in allergic diseases, and there are well-conducted
and rigorous trials in both asthma and rhinitis, [66-68],
but none on elderly: these studies failed to demonstrate
a mesurable clinical benefit on symptoms and func-
tional parameters in adults [66,67].
Phytotherapy
The traditional allopathic medicine is largely based on
subtances derived from plants and herbs (e.g. theophillyne,
salycilates, digitalis, morphine). The literature on herbal
remedies is impressive, due to the large variety of herbs
and their combinations used: tylophora indica, boswellia
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urtica and others. All these studies are in general of low
quality, but in many cases, a clinical effect can be mea-
sured in several diseases, including bronchial asthma. This
is not surprising, because most of the herbs utilized con-
tain pharmacologically active ingredients. Positive results
were obtained in rhinitis and asthma with the mixtures of
herbs used in the traditional Chinese medicine, which
contain ephedrine and atropine. No study has specifically
addressed its use in older populations. The active in-
gredients may also induce undesirable side effects
[69]. Moreover, at variance with proprietary marketing
drugs, herbal remedies carry the risk of adulteration,
incorrect collection of plants, wrong preparation and
inappropriate/incorrect dosing [70]. Products contain-
ing ginseng may negatively affect the anticoagulant
and hypoglycemic therapies [71], which may have
dramtic consequences in older individuals. Of note,
herbal remedies can be responsible for severe allergic
reaction more frequently in atopic subjects [72].
Behavioral, physical and other complementary treatments
Physical techniques (e.g. breathing control, Yoga tech-
niques and chiropractic/spinal manipulation) have been
proposed in patients with chronic respiratory illness with
the aim of improving the respiratory pattern. The major-
ity of clinical trials of chiropractic/spinal manipulation
in asthma [73,74] failed to demonstrate a clinically rele-
vant effect. Although breathing and yoga techniques can
have some effect on self-perceived well being, they cannot
be recommended as an effective treatment for asthma
[75]. Also behavioral techniques such as biofeedback and
hypnosis have been sometimes applied in asthma, gener-
ally in low quality studies, but the overview of the litera-
ture concluded for no effect [76,77].
In conclusions, available scientific evidence does not
support a role for CAM in the treatment of asthma in
the elderly. The studies in the literature often have sig-
nificant design flaws that weaken the conclusions such
as insufficient number of patients, lack of proper con-
trols and indadequate blinding.
Exercise and sport
For the elderly asthmatic, exercise represents at the
same time both a goal and a precious tool for treatment.
On the one side, in fact, regular participation in sports
and physical activity is one of the best ways for older
adults, including those with chronic diseases, to promote
independence, increase quality of life and improve aer-
obic capacity, breathing pattern, muscle strength [78].
On the other side, older asthmatics may develop a nega-
tive attitude to exercise due to a fear of symptoms occur-
ring during or after exercise and to a lack of specific
advice about exercise from specialized health professionals[79]. This lowers significantly the level of habitual activity
and physical fitness, and the result is that older asthmatic
are less active than their non-asthmatic peers [80]. To
date, the majority of studies evaluating exercise training in
asthma have been performed in children or young adults
with mild-to-moderate persistent disease. Practicing any
kind of sports in the elderly asthmatic must firstly con-
sider the physiological changes in old age: loss of muscle
mass; reduction in bone mass; increased percentage of fat;
lower amount of body water; lack of thirst; diminishing
kidney function and the very frequent presence of comor-
bidities, in particular related to the cardiovascular system.
The regressive changes in the locomotor and the nervous
system of the elderly may reduce strength, endurance, pro-
prioceptive capacity (e.g. coordination, balance) and mo-
bility [81]. While numerous studies deal with general
physiology and sports medicine aspects in the elderly, very
scant specific literature is available about asthmatic senior
subjects and sports.
Exercise-induced bronchoconstriction (EIB) with- and
without underlying asthma may occur also in the elderly
asthmatic practicing sports, even with a higher fre-
quency than in the general adult population taking into
consideration all the comorbidities and physiological
changes associated with aging previously cited. Sports
with prolonged effort of more than 5–8 minutes or in
cold and dry environments represent major risk factors
(e.g. endurance sports, cycling, cross-country skiing).
Swimming is still a controversial issue, and therefore it
should be avoided for the potential risk related to chlor-
ine byproducts inhalation. Treatment should follow the
general guidelines and recommendations that apply to
adults, with the limit of an arbitrary extrapolation due to
the paucity of specific clinical trials in patients over 65 years.
Finally, elderly athletes involved in International Associ-
ation of Athletics Federations (IAAF) or in official masters’
competitions, must be aware about anti-doping regulations
that apply not only to some anti-asthmatic drugs (beta-2
agonists except salbutamol, salmeterol and formoterol;
systemic corticosteroids) but also to several drugs widely
used to treat older adults’ comorbidities (e.g. beta-blockers,
diuretics, hormones).
Age-related and concomitant disease issues in asthma
treatment
Adherence
The contribution of patient adherence to clinical success
cannot be overestimated [82], and clinicians should al-
ways be aware of the role played by patients themselves
in determining the success or failure of treatment. These
general concepts apply perfectly to asthma, whose man-
agement is mainly based on the use of inhalation ther-
apy. In the elderly, unintentional non adherence with
inhalation therapy may lead to significant impairment in
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several chronic diseases requiring multiple medications.
Complexity of the treatment can be considered a major
risk factor for reduced adherence with medication. In
addition, elderly patients may suffer from cognitive,
hearing, or visual impairments, or other physical inabil-
ities (such as arthritis, tremor, and low coordination)
that significantly affect their ability to understand and
follow treatment regimens. Despite the evidence that
asthma related morbidity and mortality are higher in the
elderly than in the young asthmatics, the research stud-
ies and health policies on asthma have focused mainly
on children and young adults. The recently published
National Institute on Aging (NIA) white paper highlight-
ing the burden of elderly asthmatics emphasizes the
need for further research to identify and intervene on
factors affecting the disease in this under-studied group
of patients [83]. Beliefs about treatment, such as the no-
tion that treatment is not necessary or safe, are also cor-
related with decreased adherence and lower prescription
refill. The beliefs are frequently held by elderly asth-
matics, yet their influence on medication adherence has
not been demonstrated among these patients [83,84]. In
conclusion, an improvement of adherence is likely re-
quired to prevent the lack of treatment in chronic dis-
eases, and in particular in the elderly asthmatics.
Comorbidities
Aging is associated with the development of numerous
chronic diseases. Thus, it is quite common that elderly
asthmatic subjects have additional chronic diseases,
which may interfere with adherence to asthma treatment
and control. Many epidemiological studies [85,86] report
that, within the elderly population > 65 years, asthmatic
patients would have an increased incidence of additional
chronic diseases than the rest of population. Arthritis,
insomnia, gastric ulcers, migraine, sinusitis, depression,
cancer, and atherosclerosis were significantly more preva-
lent in patients with chronic airway obstruction (both
asthma and COPD) according to a Dutch study [86]. In
the US, Diette et al. reported that comorbid conditions,
specifically COPD, heartburn, and congestive heart failure,
were more prevalent in patients over 65 years of age than
younger patients [87]. Depression has been reported to
be associated to severe asthma in the elderly from U.S.
National Heart, Lung, and Blood Institute’s Severe
Asthma Research Program [88] and, in a cohort of eld-
erly inner-city asthmatic patients, depressive symptoms
were associated with poorer asthma control and quality
of life, as well as with lower rates of adherence to con-
troller medications [89].
The impact of comorbidities on asthma control of eld-
erly asthmatics has been explored by few studies with
conflicting results. According to a Canadian study [90],although more than 83% of patients with asthma who
were 55 years and older reported having one or more
major comorbidities, the odds of having asthma symp-
toms or attacks for these patients were lower than the
odds in younger. On the other hand, in the same study,
the odds of self-perceived health status as fair or poor
were significantly higher in the older respondents with
asthma (70 years and older: OR 3.10, 95% CI 2.27 – 4.12)
and those with five or more comorbidities (OR 35.18, 95%
CI 19.57 – 63.26). The recent findings from the Italian
multicenter study on elderly asthmatics (ELSA study)
showed that elderly patients with asthma associated with
COPD had worse asthma control and higher rate of severe
asthma exacerbation in the previous year, compared to
asthmatic patients without COPD [22]. In conclusion, eld-
erly asthmatic patients have many comorbidities, which,
with the possible exclusion of COPD and depression, do
not seem to have a direct impact on asthma control in pa-
tients under specialist care. Nevertheless, the comorbid
conditions in the elderly patient makes the diagnosis of
asthma more difficult, so that elderly asthmatic patients
appears to be undertreated, with the consequence of a
higher hospitalization rate and mortality.
Asthma and concomitant rhinitis
Asthma is frequently associated with nasal/sinonasal co-
morbidities such as rhinitis (allergic and non-allergic) or
chronic rhinosinusitis (with and without nasal polyps),
and these conditions may act as aggravating factors for
asthma itself. Rhinitis in the elderly seems to have peculiar
clinical and cytologic characteristics [52], and the strong
association with asthma seems to be confirmed [91,92].
Therefore, treating concomitant rhinitis or chronic rhino-
sinusitis is part of the correct and global management of
asthma also in older adults.
Antihistamines
Antihistamines are a mainstay in the treatment of allergic
respiratory diseases due to their H1 receptors antagonism.
The first-generation anti H-1 (e.g. chlorpheniramine, di-
phenhydramine) are effective on allergic inflammation but
they have well-known side effects, due to the lack of specifi-
city for the H1 receptor [93]. Sedation, anxiety, confusion
and decreased reaction time are more pronounced in the
elderly, as well as the anticholinergic effects, such as drying
of the mouth and eyes, blurred vision, disequilibrium, urin-
ary retention and constipation, arrhythmias and postural
hypertension. For these reasons symptomatic prostatic
hypertrophy, bladder neck obstruction and narrow angle
glaucoma should be taken into consideration as contraindi-
cations to the use of first-generation antihistamines [93,94].
The potential cardiac toxicity deserves some considerations.
It is not a class effect and does not occur through the H1-
receptor. Nevertheless it has been described that some
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brompheniramine, diphenhydramine in some cases are able
to prolong the QT interval, and potentially cause serious
polymorphic ventricular arrhythmias such as torsades de
pointes. These effects have been observed in case of large
doses of overdoses, however the potential cardiac comor-
bidities should be carefully assessed when prescribing an
antihistamine drug [93]. The changes in body composition
and the decreased activity of liver in the elderly may ac-
count for a major risk of adverse events associated with first
generation H1-antihistamines use [94,95].
The second-generation of H-1 receptor antagonists (e.g.
loratadine, cetirizine, fexofenadina, desloratadina, levoce-
tirizina) provide a better safety and tolerability profile due
to their low cross blood brain barrier and greater specifi-
city for their receptor [96]. The propensity of two second
generation H1-antihistamines introduced in the 1980s,
astemizole and terfenadine, to exert a cardiac toxic effect
has been described [93]. These two drugs are no longer
approved by regulatory agencies in most countries. No or
not clinically significant cardiac effects have been reported
for the second-generation H1-antihistamines loratadine,
fexofenadine, mizolastine, ebastine, azelastine, cetirizine,
desloratadine, levocetirizine, rupatadine and bilastine [96].
Second generation antihistamines have little or no sedative
or anticholinergic effect [96]. However, because of the
reduced metabolic activity, treatment should be started
with a lower dose in this age group. In fact some second-
generation H1-antihistamines such as desloratadine, lora-
tadine and rupatadine are metabolized by the system
cytochrome P450. Cetirizine is excreted largely unchanged
in the urine, and fexofenadine is excreted largely un-
changed in the feces. However interactions may be
more likely to be associated with first generation H1-
antihistamines than second-generation H1-antihista-
mines, which have a wider therapeutic index [96]. Thus
it is recommended to use second-generation antihista-
mines in the elderly.
Nasal corticosteroids
For many other classes of drugs, clinical trials with intra-
nasal steroids were generally conducted in adults, typic-
ally included those 65 years and older, but without
reporting data specific to this population. However, there
is a consensus in considering intranasal steroids as the
first-line treatment for moderate to severe allergic rhin-
itis in the elderly, effectively treating all symptoms of
rhinitis [97]. A randomized controlled trial studied the
effects of mometasone furoate nasal spray in patients
older than 65 years of age suffering from perennial aller-
gic rhinitis, showing it to be an effective treatment in
this cohort [98]. An open-label trial in 18 patients
65 years and older with a history of moderate-to-severe
rhinitis treated with either azelastine nasal spray 2 spraysper nostril bid (1.1 mg) or fluticasone propionate 2
sprays per nostril qd (200 mcg) for a 6-week study
period showed that both treatments improved symptom
scores compared to baseline, with statistically significant
improvement reached earlier for fluticasone compared
to azelastine, suggesting that fluticasone propionate is
safe and more effective than azelastine in older adults
[99]. Intranasal steroids are generally well tolerated by
older patients [100]: the most common encountered side
effects are mild epistaxis, dryness, burning and nasl
crusting. In older adults, particular attention should be
put for possible systemic side effects of intranasal ste-
roids, such as effects on bone metabolism which may
rise specific concern particularly in older and postmeno-
pausal women, and in patients receiving steroids for
other concurrent conditions such as asthma itself. How-
ever, based on the lack of significant changes in bio-
chemical markers of bone turnover in several studies,
these intranasal corticosteroids agents do not appear to
be associated with reductions in bone mineral density or
osteoporosis [101,102].
Another concern in using intranasal corticosteroids in
older patients is the possible effect of these agents in fos-
tering glaucoma. A case–control study of 9793 patients,
age 66 or older, with a new diagnosis of borderline glau-
coma, open angle glaucoma, or ocular hypertension, and
38325 controls randomly selected showed that there was
no increased risk for these diseases with intranasal steroid
use. The risk of ocular side effects appears to be negligible
due to the low systemic bioavailability of most available in-
tranasal steroid preparations [103]. In conclusion, intrana-
sal corticosteroids have the most favorable safety and
efficacy profiles in older individuals and therefore they
should be recommended as first-line treatment of rhinitis
or chronic rhinosinusitis in older patients [104].
Topical antihistamines
Topically administered antihistamines are clinically ef-
fective, with the advantage of delivering the medication
directly to the target area. Common adverse events of
inhaled antihistamines are usually mild and include bit-
ter taste, headache, dry mouth, sedation and application
site irritation. More relevant side effects, mainly related
to the first generation molecules, including urinary re-
tention, prolonged QT interval, arrhythmias and consti-
pation are however more prevalent in elderly patients
due to the commonly observed comorbidities, such as
heart diseases, prostatic hypertrophy and narrow angle
glaucoma. Moreover, elderly patients usually take many
drugs, thus increasing the risk of interaction between
medications. Therefore, the antihistamine selection for
the treatment of concomitant allergic rhinitis in elderly
asthmatic patients should be made carefully and topical II
generation molecules should be preferred [94]. In subjects
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tolerated [105]. Furthermore, pharmacokinetic studies in-
dicate that the systemic bioavailabilities of marketed aze-
lastine hydrochloride nasal spray products is about 40%
and that 75% of the excretion of its metabolites is through
faeces while just 25% is through urines, making it safer
also for patients with renal impairment [106]. Levocabas-
tine is mainly (about 70% of the absorbed dose) excreted
unchanged in the urine, and has to be therefore used with
caution in patients with renal impairment. After intranasal
administration, low plasma concentrations of levocabas-
tine are reached; therefore, drug interactions are not clin-
ically significant, excluding those with inhibitor of
cytochrome P450, such as erythromycin and ketoconazole.
No clinically significant mean changes from baseline in
QT or QTc intervals were reported in literature [107].
At last, a novel intranasal formulation, combining the
second generation antihistamine azelastine hydrochlor-
ide and fluticasone propionate in a single device, has
been recently developed, showing superiority over its
single components [108]. Although these studies have
been performed in a general adult population, we can
reasonably assume the combination could be effectively
and safely used also in elderly patients. Furthermore, the
administration of different drugs in the same preparation
could facilitate the compliance for older patients.
Conclusions
Final considerations and novel perspectives
The most recent research identified some promising “bio-
logical” approaches that could be successfully applied also
in the elderly, and new treatment modalities have been in-
troduced, mainly concerning biological agents or im-
munotherapy developments [109] (Table 2). Of note, thereTable 2 The most advanced biological preparations used
in asthma
Drug Target Function
Atrakincept Anti-IL4 Binds IL-4 thus blocking the interaction
with its receptor. Reduces the
proliferation of Th2 lymphocytes.
Phase II
Pascolizumab
Benralizumab Anti IL-5 receptor Reduces the proliferation and
activation of eosinophils. Phase II
Daclizumab Anti CD-25 Blocks the receptor for IL-2
Kerliximab Anti CD-4 Reduces the proliferation of CD4+
lymphocytes. Phase II
Mepolizumab Anti IL-5 Reduces the proliferation and
activation of eosinophils. Phase III
Reslizumab
Omalizumab Anti IgE Complexes circulating IgE and
impedes their binding to receptor.
Commercialized
Pitakinra IL-4 mutein Competes with IL-4 and IL-13 receptor.
Phase IIIis no upper limit of age for the prescription of omalizu-
mab, thus it can be used also in the elderly, provided that
a clear diagnosis of IgE-mediated disease is made. The im-
mediately following option is the anti IL-5 Mab (mepoli-
zumab, reslizumab). This approach is mainly targeted to
uncontrolled asthma with a clearly demonstrated eosino-
philia, and there is, so far, no apparent contraindication to
its use also in the elderly. Possible molecular targets, at
least in asthma, are IL-4 and IL-13, both involved in atopy
related inflammatory processes, and partly sharing the
same receptor. Thus, targeting IL-4 or IL-13 alone may be
ineffective because of redundant mechanisms of the two
cytokines. Based on this concept, pitrakinra, an IL-4Ra
double mutein involved in both IL-4 and IL-13 signalling,
was developed and tested in asthma clinical trials with
favourable results [110]. In addition, anti CD25 (daclizu-
mab) and anti IL-5 (benralizumab) receptors are currently
being explored [109].
For about one century, specific immunotherapy has been
administered only subcutaneously, but in the last 20 years,
the sublingual route has been accepted as a viable alterna-
tive, and its use is nowadays largely diffused [50]. This mo-
dality could represent an optimal choice in the elderly,
where convenience, including the at home administration,
remains the most important issue. However, clinical trials
of immunotherapy in the elderly are rare and sparse, and
senior subjects were enrolled only on an anecdotal way.
For allergen immunotherapy, several alternative modalities
are currently being developed, including the new routes of
administration, the preparation of extracts and the use of
adjuvants (Table 3). Within those approaches, the intra-
lymphatic and the epicutaneous administration routes
seem to be the more feasible in the immediate future, and
particularly suitable for elderly, due to the non invasive or
not time-consuming approach [111]. Considering that the
IgE response to allergens not always declines with age, the
association/combination with Th1-inducing adjuvants is a
promising approach. Indeed, there are already available
commercial preparations of allergens adjuvanted with
bacteria-derived components, which stimulate the toll like
receptor 4. The use of bacterial DNA as stimulants of the
toll-like receptor 9, to be associated with allergens is an in-
triguing possibility [112]. Similarly, good results have been
obtained with the recombinant allergenic molecules, butTable 3 The recent developments of allergen
immunotherapy
Formulation Allergen
Subcutaneous/sublingual Recombinant
Epicutaneous Purified
Intralymphatic Bacteria-derived adjuvants
Micro-injection DNA-derived adjuvants
Allergen peptides
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fact that a specific mixture of allergen proteins would be
required [113]. In this regard, the component-resolved
diagnosis would facilitate the appropriate prescription of
immunotherapy, by discerning true sensitizations and
cross-reactivities [114].
For long time, it was assumed that allergic respiratory
disorders are typical of children, adolescents and young
adults. In fact, most clinical trials were designed to in-
clude patients below 65 years of age. The time has come
to face with allergic diseases in older ages, and this car-
ries safety concerns and implications for efficacy. The
management of allergic asthma in the elderly will only
be successful when clinical randomized trials and obser-
vational real-life studies will be specifically conceived for
older individuals.
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